ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Santa Clara Valley Medical Center (SCVMC) in San Jose, Calif. has signed an agreement to participate in the CancerLinQ® platform.
ASCO has released a Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce, which aims to promote the development of an oncology workforce that is culturally competent and equipped to care for a diverse population of patients with cancer.
ASCO applauds Congress for its leadership in providing an additional $2 billion in funding for the National Institutes of Health (NIH). This increase reaffirms the United States' longstanding, bipartisan commitment to scientific research, and will reinvigorate the scientific community as it continues to rebuild after a decade of flat funding. It also offers hope to millions of Americans and their families who face a cancer diagnosis every year.
ASCO strongly opposes the American Health Care Act (AHCA) as currently proposed, and urges a “No” vote on the bill in the House of Representatives because it does not meet our previously announced principles. We believe healthcare reform must ensure meaningful access to high-quality care for any American with cancer.
ALEXANDRIA, Va. —The American Society of Clinical Oncology (ASCO) today issued a provisional clinical opinion (PCO) on the use of second-line hormonal therapy for men with castration-resistant prostate cancer (CRPC) who have not yet received chemotherapy.
ASCO applauds the California legislature for being the first state body of lawmakers in the nation to consider legislation that is designed to specifically improve clinical pathways in oncology. Clinical pathways, when appropriately designed and implemented, are evidence-based treatment management tools used to support delivery of high-quality cancer care for specific patient presentations.
ALEXANDRIA, Va. – Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, will be highlighted in the official Press Program for the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Research results will be released in advance of and throughout the Annual Meeting, taking place June 2-6 in Chicago.
The American Society of Clinical Oncology (ASCO) opposes payer-imposed utilization management policies that restrict patient access to high-quality, high-value cancer care. In a statement released today, ASCO asserts that in modern cancer care there is frequently a lack of interchangeable clinical options, and that optimal cancer care requires patient access to the most medically appropriate drug at the most opportune time based on the highest quality evidence.
The American Society of Clinical Oncology (ASCO) today announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017-2018 ASCO Health Policy Fellowship program, now entering its second year.
ALEXANDRIA, Va. — Today, the American Society of Clinical Oncology, Inc. (ASCO®) announced that Instituto de Oncologia do Vale (IOV) has become the first practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program, LLC (QCP). IOV is the second international practice to achieve this milestone in demonstrating the quality of care it provides to oncology patients.
In a position statement released today, The American Society of Clinical Oncology (ASCO) stated its support for increased access to investigational new treatment options for patients with cancer, while raising serious concerns about recently proposed federal "right-to-try" (RTT) legislation as well as enacted state RTT laws. ASCO said these measures lack adequate patient protections and do not remove any of the major barriers patients face in accessing investigational drugs outside of clinical trials.
ALEXANDRIA, Va. -- The American Society of Clinical Oncology, Inc. (ASCO®) today issued recommendations addressing the needs of sexual and gender minority (SGM) populations as they relate to cancer. The recommendations, published in a policy statement in the Journal of Clinical Oncology, are designed to focus attention on the challenges facing the SGM community--including discrimination and greater risk of anxiety and depression, resulting in disparate care--and concrete steps that can help minimize health disparities among SGM individuals.
“This report confirms a trend – ongoing for several decades now – that fewer people are dying from cancer than ever before. America’s federal investment in biomedical research has fueled discoveries and insights that help us better prevent, diagnose, and treat cancer. The more than 15 million cancer survivors alive today are living proof that this investment pays major dividends."
The American Society of Clinical Oncology (ASCO) has released a set of recommendations to enhance the role of observational cancer research in clinical decision-making. Published in the Journal of Clinical Oncology (JCO), the ASCO research statement discusses the expanding opportunities to utilize observational studies to advance cancer research and supplement the knowledge gained through cancer clinical trials.
Alexandria, Va.—CancerLinQ LLC is partnering with the leading association for hematology/oncology pharmacy professionals, the Hematology/Oncology Pharmacy Association (HOPA). CancerLinQ will draw on the expertise of HOPA and its members as it continues to roll out CancerLinQ’s core quality improvement and data-sharing platform to oncology practices and cancer centers. Beginning next year, HOPA will have access to data-driven insights from CancerLinQ Discovery™ to educate its member pharmacists, who play a vital role in the cancer care team.